“…Signaling pathways include cytokine signaling in immune system [48], extracellular matrix organization [49], diseases of metabolism [50], hemostasis [51], innate immune system [52], metabolism of lipids [53] [87], CES1 [88], CYP19A1 [89], PLAC8 [90], CD36 [91], GIPR (gastric inhibitory polypeptide receptor) [92], ARG1 [93], MSR1 [94], DOCK2 [95], S1PR1 [96], OXTR (oxytocin receptor) [97], F11R [98], LEPR (leptin receptor) [99], AR (androgen receptor) [100], DKK3 [101], FOXO1 [102], PIK3CB [103], WWP1 [104], PHIP (pleckstrin homology domain interacting protein) [105], MPZL3 [106], FBXO2 [107], GUCY2C [108], ADRA2A [109], CHRNA5 [110], GLP2R [111], SDC3 [112], NFAT5 [113], PON2 [114], PRNP (prion protein) [115], DGKE (diacylglycerol kinase epsilon) [116], ARHGAP21 [117], COQ2 [118], EPHX2 [119] and FAM3C [120] were observed to be associated with the progression of obesity. Vargas-Alarcón et al [ [133], Jiang et al [134], Yu et al [135], Jiang et al [136], Huang et al [137], Scuruchi et al [138], Wang et al [139], Ibrahim et al [140], Zha et al …”